Weaver C. Barksdale & Associates, Inc. / ABBV
Weaver C. Barksdale & Associates, Inc.’s Abbvie Inc Position
Does Weaver C. Barksdale & Associates, Inc. own Abbvie Inc (ABBV)? Yes — 9.9K shares worth $2M (+2.05% of its 13F portfolio) as of Q1 2026, up from 9.3K shares the prior filed quarter.
Position Value
$2M
Q1 2026
Shares
9.9K
% of Portfolio
+2.05%
Quarters Held
18
currently held
Position History ABBV
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 9.9K | $2M | +2.05% |
| Q4 2025 | 9.3K | $2M | +2.23% |
| Q3 2025 | 10.4K | $2M | +2.32% |
| Q2 2025 | 11.1K | $2M | +1.97% |
| Q1 2025 | 11.2K | $2M | +2.25% |
| Q4 2024 | 11.4K | $2M | +1.95% |
| Q3 2024 | 11.7K | $2M | +2.08% |
| Q2 2024 | 12.1K | $2M | +1.98% |
| Q1 2024 | 12.3K | $2M | +2.06% |
| Q4 2023 | 12.4K | $2M | +1.88% |
| Q3 2023 | 15.6K | $2M | +1.98% |
| Q2 2023 | 13.0K | $2M | +1.73% |
| Q1 2023 | 13.7K | $2M | +2.05% |
| Q4 2022 | 14.4K | $2M | +2.05% |
| Q3 2022 | 14.1K | $2M | +1.89% |
| Q2 2022 | 14.6K | $2M | +2.07% |
| Q1 2022 | 18.0K | $3M | +2.60% |
| Q4 2021 | 17.8K | $2M | +2.18% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Weaver C. Barksdale & Associates, Inc.’s full portfolio or all institutional holders of ABBV.